{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:54:54Z","timestamp":1771005294180,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1796,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/jto.0b013e3181f94ad4","type":"journal-article","created":{"date-parts":[[2010,11,25]],"date-time":"2010-11-25T04:55:34Z","timestamp":1290660934000},"page":"109-114","source":"Crossref","is-referenced-by-count":45,"title":["BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin\/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"John D.","family":"Hainsworth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane E.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Faoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Azzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181f94ad4_bib1","series-title":"Cancer Facts & Figures 2009","author":"American Cancer Society","year":"2009"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib2","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib3","article-title":"Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage in patients with advanced NSCLC receiving bevacizumab","author":"Novotny","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2008.16.2412","article-title":"Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab","volume":"27","author":"Sandler","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib5","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib6","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non\u2013small-cell lung cancer: AVAiL","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib7","series-title":"Data-on-file","year":"2009"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib8","series-title":"Data-on-file","year":"2009"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.1995.13.5.1221","article-title":"Prognostic factors for survival in advanced non\u2013small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients","volume":"13","author":"Paesmans","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2005.04.177","article-title":"Clinical model to predict survival in chemonaive patients with advanced non\u2013small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data","volume":"23","author":"Hoang","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib11","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/mol.104.009373","article-title":"Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells","volume":"68","author":"Giovannetti","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib13","doi-asserted-by":"crossref","unstructured":"Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract 6521]. European Cancer Conference, Barcelona, Spain, September 23, 2007.","DOI":"10.1016\/S1359-6349(07)71349-6"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib14","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJM198710083171504","article-title":"Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung","volume":"317","author":"Rodenhuis","year":"1987","journal-title":"N Engl J Med"},{"issue":"15s","key":"10.1097\/JTO.0b013e3181f94ad4_bib16","article-title":"Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer","volume":"27","author":"Karp","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib17","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2009.23.6745","article-title":"Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1","volume":"27","author":"Tolcher","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1097\/JTO.0b013e3181f94ad4_bib18","article-title":"A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule","volume":"26","author":"Hidalgo","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15s","key":"10.1097\/JTO.0b013e3181f94ad4_bib19","article-title":"Axitinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(09)70002-6","article-title":"Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I\/II study","volume":"10","author":"Cohen","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Suppl 18","key":"10.1097\/JTO.0b013e3181f94ad4_bib21","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/jco.2006.24.18_suppl.5530","article-title":"A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC) [abstract]","volume":"24","author":"Seiwert","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 18","key":"10.1097\/JTO.0b013e3181f94ad4_bib22","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1200\/jco.2007.25.18_suppl.6034","article-title":"Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC) [abstract]","volume":"25","author":"Choong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f94ad4_bib23","unstructured":"Enzinger PC, Fidias P, Meyerhardt J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. ASCO Gastrointestinal Cancers Symposium, 2006: Abstract 68."}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415319031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415319031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T02:33:54Z","timestamp":1592102034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415319031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1556086415319031"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181f94ad4","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}